|
|
Article: New Study Shows Reduction in Bone Metastases for Patients Taking Oral Clodronate (BONEFOS(R)).
- Article from:
- PR Newswire Europe
- Article date:
- March 27, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NICE, France, March 27 /PRNewswire/ --
- Data Presented at the 2006 European Breast Cancer Conference Highlights the Relationship between Bone Turnover Response and Incidence of Bone Metastases
According to recent trial findings, Bonefos(R) (oral clodronate) plus standard adjuvant therapy in primary breast cancer is associated with both reduced bone turnover and protection against bone metastases. The results, presented during the 5th annual European Breast Cancer Conference (EBCC), demonstrated that women treated with oral Bonefos for two years significantly reduced their chances of developing bone metastases within the first five years ...